{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:34:41Z","timestamp":1767141281666,"version":"build-2238731810"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Improvements in both musculoskeletal and non-musculoskeletal manifestations are important treatment goals in psoriatic arthritis (PsA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>These post hoc analyses determined whether additional benefits related to various PsA domains are observed in patients simultaneously achieving 50% improvement in American College of Rheumatology criteria (ACR50) and 100% improvement in Psoriasis Area Severity Index (PASI100), the primary endpoint of the SPIRIT-H2H study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with active PsA and psoriasis in SPIRIT-H2H (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009566) were categorised into two sets of four response groups irrespective of treatment allocation (approved dosages of ixekizumab or adalimumab): patients who simultaneously achieved ACR50 and PASI100 response, achieved ACR50 response only, achieved PASI100 response only, or did not achieve ACR50 or PASI100 response after 24 and 52\u00a0weeks of treatment. Patients achieving simultaneous ACR50 and PASI100 response were compared with the other patient response groups at the corresponding time point for efficacy and health-related quality of life (HRQoL) outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients simultaneously achieving ACR50 and PASI100 responses at week 24 or 52 showed higher rates of ACR70 response, minimal disease activity, Disease Activity in Psoriatic Arthritis\u2009\u2264\u20094, resolution of enthesitis and dactylitis, and HRQoL improvement at weeks 24 and 52, respectively, than the other corresponding response groups at both time points.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High levels of disease control, such as those obtained with simultaneous achievement of ACR50 and PASI100 response, were linked to better outcomes across a wide range of endpoints that are important for patients with PsA. Patients meeting this combined endpoint showed more comprehensive and thus greater control of disease activity.<\/jats:p>\n                    <jats:p>Trial registration<\/jats:p>\n                    <jats:p>NCT03151551<\/jats:p>\n                    <jats:p>\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                \u2022\n                                <jats:italic>Treatment goals for patients with psoriatic arthritis emphasise the importance of improving both musculoskeletal and non-musculoskeletal manifestations of the disease<\/jats:italic>\n                                .\u2022\n                                <jats:italic>A combined endpoint considering both these manifestations, achievement of at least 50% improvement in American College of Rheumatology criteria and 100% improvement in Psoriasis Area Severity Index, was linked with achievement of a number of other endpoints relevant to psoriatic arthritis, including health-related quality of life that are important to patients with psoriatic arthritis<\/jats:italic>\n                                .\u2022\n                                <jats:italic>Patients meeting the combined endpoint were more likely to achieve a disease state of remission, which is the stated aim of treatment for psoriasis<\/jats:italic>\n                                .\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-021-05891-5","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T08:31:28Z","timestamp":1631521888000},"page":"4943-4954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7186","authenticated-orcid":false,"given":"Frank","family":"Behrens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2812-3980","authenticated-orcid":false,"given":"Soyi Liu","family":"Leage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-7129","authenticated-orcid":false,"given":"Christophe","family":"Sapin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7212-1835","authenticated-orcid":false,"given":"Celine El","family":"Baou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"De La Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Meszaros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8740-9615","authenticated-orcid":false,"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4002-1861","authenticated-orcid":false,"given":"Bernard","family":"Combe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5932","authenticated-orcid":false,"given":"Filip","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4528-310X","authenticated-orcid":false,"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"5891_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis [published correction appears in N Engl J Med 2017;376:2097]. N Engl J Med 376:957\u2013970. https:\/\/doi.org\/10.1056\/NEJMra1505557","journal-title":"N Engl J Med"},{"key":"5891_CR2","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79:700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"5891_CR3","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","volume":"59","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates LC, Gladman DD (2020) Treatment guidelines in psoriatic arthritis Rheumatology (Oxford) 59(Suppl 1):i37\u2013i46. https:\/\/doi.org\/10.1093\/rheumatology\/kez383","journal-title":"Treatment guidelines in psoriatic arthritis Rheumatology (Oxford)"},{"key":"5891_CR4","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer ML, Armstrong AW et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68:1060\u20131071. https:\/\/doi.org\/10.1002\/art.39573","journal-title":"Arthritis Rheumatol"},{"key":"5891_CR5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/annrheumdis-2018-215003","volume":"78","author":"A Kavanaugh","year":"2019","unstructured":"Kavanaugh A, Gottlieb A, Morita A, Merola JF, Lin C-Y, Birt J, Shuler CL, Hufford MM, Tha\u00e7i D (2019) The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann Rheum Dis 78:1215\u20131219. https:\/\/doi.org\/10.1136\/annrheumdis-2018-215003","journal-title":"Ann Rheum Dis"},{"key":"5891_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","volume":"79","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Smolen JS, Behrens F, Nash P, Leage SL, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS, SPIRIT H2H study group (2020) A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 79:123\u2013131. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215386","journal-title":"Ann Rheum Dis"},{"key":"5891_CR7","unstructured":"Eli Lilly and Company (2020) Taltz (ixekizumab). Prescribing information. https:\/\/uspl.lilly.com\/taltz\/taltz.html#pi. Accessed 17 Sep 2020"},{"key":"5891_CR8","unstructured":"Eli Lilly Nederland B.V. (2020) Taltz (ixekizumab). Summary of product characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/taltz-epar-product-information_en.pdf. Accessed 7 July 2020"},{"key":"5891_CR9","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Grata\u0107os J, Goupille P, Leage SL, Pillai S, Nash P (2020) Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis 79:1310\u20131319. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217372","journal-title":"Ann Rheum Dis"},{"key":"5891_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2217\/ijr.12.63","volume":"7","author":"L Eder","year":"2012","unstructured":"Eder L, Chandran V, Gladman DD (2012) Gender-related differences in patients with psoriatic arthritis. Int J Clin Rheumatol 7:641\u2013649","journal-title":"Int J Clin Rheumatol"},{"key":"5891_CR11","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1002\/acr.24090","volume":"72","author":"AM Orbai","year":"2020","unstructured":"Orbai AM, Perin J, Gorlier C, Coates LC, Kiltz U, Leung YY, Palominos PE, Ca\u00f1ete JD, Scrivo R, Balanescu A, Dernis E, T\u00e4lli S, Ruyssen-Witrand A, Soubrier M, Aydin S, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, Smolen JS, de Wit M, Gossec L (2020) Determinants of patient-reported psoriatic arthritis impact of disease: an analysis of the association with sex in 458 patients from fourteen countries. Arthritis Care Res (Hoboken) 72:1772\u20131779. https:\/\/doi.org\/10.1002\/acr.24090","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl1","key":"5891_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/annrheumdis-2021-eular.1575","volume":"80","author":"I van der Horst-Bruinsma","year":"2021","unstructured":"van der Horst-Bruinsma I, Nurmohamed M, Van Kuijk A, Siebert S, Bergmans P, De Vlam K, Gremese E, Joven-Ib\u00e1\u00f1ez B, Korotaeva T, Noel W, Sfikakis P, Theander E, Smolen JS, Gossec L (2021) Female versus male burden of psoriatic arthritis is higher and treatment persistence shorter after ustekinumab or tumour necrosis factor inhibitor treatment: 1-year data from the PSABIO Study (abstract OP0232). Ann Rheum Dis 80(Suppl 1):142","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 11","key":"5891_CR13","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1002\/acr.20577","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ (2011) Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 63(Suppl 11):S64\u2013S85","journal-title":"Arthritis Care Res (Hoboken)"}],"updated-by":[{"DOI":"10.1007\/s10067-021-05966-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000}}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05891-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05891-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05891-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T03:13:37Z","timestamp":1645067617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05891-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5891"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05891-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"assertion":[{"value":"28 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Funding information has been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10067-021-05966-3","URL":"https:\/\/doi.org\/10.1007\/s10067-021-05966-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SPIRIT-H2H was conducted in accordance with the ethical principles of the Declaration of Helsinki; all patients provided written informed consent and the study protocol was approved by the ethical review board (17\/LO\/0794) prior to the start of study-related procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Frank Behrens has received research grants from Celgene, Chugai, Janssen, Pfizer, and Roche and consultation\/speaker fees from AbbVie; Boehringer Ingelheim; Celgene; Chugai; Eli Lilly and Company; Genzyme; Gilead Sciences, Inc.; Janssen; Merck; Novartis; Pfizer; Roche; Sanofi; and UCB. Soyi Liu Leage and Celine El Baou are employees of Eli Lilly and Company. Christophe Sapin, Inmaculada De La Torre, and Gabriella Meszaros are shareholders and employees of Eli Lilly and Company. Georg Schett has served on speakers bureaus for AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, Roche, and UCB. Bernard Combe has received grant\/research support from Novartis, Pfizer, and Roche-Chugai; served as a consultant for AbbVie; Eli Lilly and Company; Gilead Sciences, Inc.; Janssen; Pfizer; Roche-Chugai; and Sanofi; and served on speakers bureaus for Bristol Myers Squibb; Eli Lilly and Company; Gilead Sciences, Inc.; Merck Sharp & Dohme; Pfizer; and Roche-Chugai. Filip van den Bosch has received grant\/research support from AbbVie, Merck, and UCB; served as a consultant for AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Sanofi, and UCB Pharma; and served on speakers bureaus for AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Galapagos, Janssen, Merck, Novartis, Pfizer, Sanofi, and UCB Pharma. Laure Gossec has received grant\/research support from Amgen, Eli Lilly and Company, Galapagos, Janssen, Pfizer, Sandoz, and Sanofi and consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Biogen, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, and UCB.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}